Lundbeck meets Phase II depression endpoint

H. Lundbeck A/S (CSE:LUN) said top-line results from a Phase II trial to treat major depressive disorder showed 5, 10 and 20 mg Lu AA24530 met the primary endpoint of a significant improvement in Montgomery-Asberg depression rating scale (MADRS) scores vs. placebo after six weeks from baseline. The active comparator, 60 mg duloxetine, also produced a significant improvement compared to placebo in the double-blind study in 652 patients. ...